Afficher la notice abrégée

Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia

dc.rights.licenseopenen_US
dc.contributor.authorJOHNSON-ANSAH, Hyacinthe
dc.contributor.authorMANEGLIER, Benjamin
dc.contributor.authorHUGUET, Francoise
dc.contributor.authorLEGROS, Laurence
dc.contributor.authorESCOFFRE-BARBE, Martine
dc.contributor.authorGARDEMBAS, Martine
dc.contributor.authorCONY-MAKHOUL, Pascale
dc.contributor.authorCOITEUX, Valerie
dc.contributor.authorSUTTON, Laurent
dc.contributor.authorABARAH, Wajed
dc.contributor.authorPOUATY, Camille
dc.contributor.authorPIGNON, Jean-Michel
dc.contributor.authorCHOUFI, Bachra
dc.contributor.authorVISANICA, Sorin
dc.contributor.authorDEAU, Benedicte
dc.contributor.authorMORISSET, Laure
dc.contributor.authorCAYSSIALS, Emilie
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMOLIMARD, Mathieu
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBOUCHET, Stephane
dc.contributor.authorMAHON, Francois-Xavier
dc.contributor.authorNICOLINI, Franck
dc.contributor.authorAEGERTER, Philippe
dc.contributor.authorCAYUELA, Jean-Michel
dc.contributor.authorDELORD, Marc
dc.contributor.authorBRUZZONI-GIOVANELLI, Heriberto
dc.contributor.authorROUSSELOT, Philippe
dc.date.accessioned2022-10-28T06:59:06Z
dc.date.available2022-10-28T06:59:06Z
dc.date.issued2022-08-12
dc.identifier.issn1999-4923 (Print) 1999-4923 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/170131
dc.description.abstractEnThe registered dose for imatinib is 400 mg/d, despite high inter-patient variability in imatinib plasmatic exposure. Therapeutic drug monitoring (TDM) is routinely used to maximize a drug's efficacy or tolerance. We decided to conduct a prospective randomized trial (OPTIM-imatinib trial) to assess the value of TDM in patients with chronic phase chronic myelogenous treated with imatinib as first-line therapy (NCT02896842). Eligible patients started imatinib at 400 mg daily, followed by imatinib [C]min assessment. Patients considered underdosed ([C]min < 1000 ng/mL) were randomized in a dose-increase strategy aiming to reach the threshold of 1000 ng/mL (TDM arm) versus standard imatinib management (control arm). Patients with [C]min levels >/= 1000 ng/mL were treated following current European Leukemia Net recommendations (observational arm). The primary endpoint was the rate of major molecular response (MMR, BCR
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enImatinib
dc.subject.enTherapeutic drug monitoring
dc.subject.enChronic myelogenous leukemia
dc.title.enImatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia
dc.typeArticle de revueen_US
dc.identifier.doi10.3390/pharmaceutics14081676en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed3601530en_US
bordeaux.journalPharmaceuticsen_US
bordeaux.page1676en_US
bordeaux.volume14en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue8en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamAHEAD_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03832869
hal.version1
hal.date.transferred2022-10-28T06:59:11Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Pharmaceutics&rft.date=2022-08-12&rft.volume=14&rft.issue=8&rft.spage=1676&rft.epage=1676&rft.eissn=1999-4923%20(Print)%201999-4923%20(Linking)&rft.issn=1999-4923%20(Print)%201999-4923%20(Linking)&rft.au=JOHNSON-ANSAH,%20Hyacinthe&MANEGLIER,%20Benjamin&HUGUET,%20Francoise&LEGROS,%20Laurence&ESCOFFRE-BARBE,%20Martine&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BPH_pharmaceutics_2022_Johnson.pdf
Taille:
1.098Mo
Format:
PDF
Voir/Ouvrir
Thumbnail
Nom:
license_rdf
Taille:
914octets
Format:
application/rdf+xml
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée